Ono Pharmaceutical Co., Ltd.

Other

Yoshinori Ii

Takahiro Ogawa

Seiei Sasatani

Masashi Shiota

Shinichi Yasueda

Tadashi Terai

Noboru Sekiya

Hiroshi Azuma

Masayuki Ishikawa

A sustained-release formulation of 5-acetyl-4,6-dimethyl-2-[2-[4-(2-methoxyphenyl)piperazinyl]ethylamino]pyrimidine trihydrochloride coated with a release-controlling film comprising a water-insoluble polymer film having no hydrophilic group. The formulation of the present invention has such a release pattern that the drug release lasts for 20 hours or more, so that can be appropriately administered for treatment. Furthermore, the formulation itself is so stable that its release pattern does not change with pH and the formulation does not suffer from deterioration, coloration and the like with the lapse of time.

Sustained-release preparation containing 5-acetyl-4,6-dimethyl-2[2-[4-(2-methoxyphenyl) piperazinyl]ethylamino] pyrimidine trihydrochloride as active ingredient

In order to promote solubilization or suspension of 4-oxo-8-&lsqb;4-(4-phenylbutoxy)benzoylamino&rsqb;-2-(tetrazol-5-yl)-4H-1-benzopyran or its hydrate (pranlukast) in water, at least one component selected from surfactants, water-soluble cellulose derivatives and water-soluble vinyl polymers is formulated together with pranlukast. Thus, it is possible to provide an aqueous liquid pharmaceutical composition containing higher concentration of pranlukast and having good properties.

Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative

Granules containing pranlukast, process for producing the granules, and

Growing community of inventors

Mishima-gun, Japan

Yoshinori Ii